Skip to main content

Clinical Trials Search at Vanderbilt-Ingram Cancer Center



A Study to Evaluate The Efficacy And Safety Of RO7198457 In Combination With Pembrolizumab Versus Pembrolizumab Alone In Participants With Previously Untreated Advanced Melanoma.

Melanoma

This study will evaluate the efficacy, safety, pharmacokinetics, and patient-reported outcomes (PROs) of RO7198457 plus pembrolizumab compared with pembrolizumab alone in patients with previously untreated advanced melanoma.
Melanoma
II
Johnson, Douglas
NCT03815058
VICCMEL1958

Safety and Efficacy of Tenalisib (RP6530) in Combination With Romidepsin in Patients With Relapsed / Refractory T-cell Lymphoma

Lymphoma

To characterize safety, tolerability and to establish the maximum tolerated dose (MTD) of Tenalisib in combination with Romidepsin in patients with R / R T-cell lymphoma.
Lymphoma
I/II
Reddy, Nishitha
NCT03770000
VICCPCL1937

Study Evaluating Brexucabtagene Autoleucel (KTE-X19) in Pediatric and Adolescent Participants With Relapsed / Refractory B-precursor Acute Lymphoblastic Leukemia or Relapsed / Refractory B-Cell Non-Hodgkin Lymphoma

Pediatric Leukemia

The primary objectives of this study are to evaluate the safety and efficacy of brexucabtagene autoleucel (KTE-X19) in pediatric and adolescent participants with relapsed / refractory (r / r) B-precursor acute lymphoblastic leukemia (ALL) or relapsed or refractory (r / r) B-cell non-Hodgkin lymphoma (NHL).
Pediatric Leukemia
I/II
Kitko, Carrie
NCT02625480
VICCPED15143

Safety and Efficacy of Axicabtagene Ciloleucel in Combination With Either Rituximab or Lenalidomide in Participants With Refractory Large B-Cell Lymphoma

Lymphoma

The primary objective of this study is to estimate the efficacy of axicabtagene ciloleucel in combination with either rituximab or lenalidomide, as measured by assessment of response rates in adult participants with relapsed / refractory large B-cell lymphoma.
Lymphoma
II
Oluwole, Olalekan
NCT04002401
VICCCTT19106

Study of TJ011133 Subjects With Relapsed / Refractory Advanced Solid Tumors and Lymphoma

Multiple Cancer Types

The purpose of this study is to assess the safety and tolerability of TJ011133 in participants with solid tumors and lymphoma.
Miscellaneous, Phase I
I
Berlin, Jordan
NCT03934814
VICCPHI1944

Trial of AB-205 in Adults With Lymphoma Undergoing High-Dose Therapy and Autologous Stem Cell Transplantation

Multiple Cancer Types

A phase 1, open label, multi-center trial of AB-205 in adults with Hodgkin or non-Hodgkin lymphoma who are in chemo-sensitive remission undergoing high-dose therapy, with or without radiation, and autologous stem cell transplantation (HDT-ASCT). Subjects will receive AB-205 infusion following autologous stem cell transfusion on Day 0.
Lymphoma, Phase I
I
Dholaria, Bhagirathbhai
NCT03925935
VICCCTTP1919

A Study to Investigate BAY2402234, a Dihydroorotate Dehydrogenase (DHODH) Inhibitor, in Myeloid Malignancies

Multiple Cancer Types

The primary objective is to determine the safety, tolerability, pharmacokinetics, maximum tolerated dose (MTD), or pharmacological active dose (PAD) of BAY2402234 in patients with acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), or chronic myelomonocytic leukemia (CMML). The secondary objective is to evaluate evidence of clinical efficacy associated with BAY2402234 in patients with AML (defined as Complete remission, Complete remission with partial hematologic recovery), and MDS (defined as hematological improvement).
Hematologic, Leukemia, Myelodysplastic Syndrome, Phase I
I
Savona, Michael
NCT03404726
VICCHEMP1826

A Study of ZN-c5 in Participants With Breast Cancer

Breast

This is a Phase 1 open-label, multicenter study to evaluate biomarkers for ZN-c5 in subjects with breast cancer
Breast
I
Abramson, Vandana
NCT04176757
VICCBREP19108

A Study of Subcutaneous Daratumumab Regimens in Combination With Bispecific T Cell Redirection Antibodies for the Treatment of Participants With Multiple Myeloma

Multiple Myeloma

The purpose of this study is to identify recommended Phase 2 doses (RP2Ds) for each treatment combination (between daratumumab plus talquetamab and teclistamab plus daratumumab) and to characterize the safety of each RP2D for selected treatment combinations.
Multiple Myeloma
I
Dholaria, Bhagirathbhai
NCT04108195
VICCHEMP1995

First in Human Study of M4344 in Participants With Advanced Solid Tumors

Multiple Cancer Types

The purpose of this study is to evaluate the safety and tolerability of multiple ascending doses of single-agent M4344 administered twice-weekly (BIW), twice daily (BID) or once daily dose schedule in participants with advanced solid tumors. This investigation is a three part study examining M4344 alone and in combination with carboplatin to determine the safety and maximum tolerated dose.
Lymphoma, Ovarian, Phase I
I
Berlin, Jordan
NCT02278250
VICCPHI14126

To learn more about any of our clinical
trials, call 1-800-811-8480 or complete
the online Self-Referral Form here: